Shandong Realcan Pharmaceutical Co Ltd - Asset Resilience Ratio
Shandong Realcan Pharmaceutical Co Ltd (002589) has an Asset Resilience Ratio of -4.18% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Shandong Realcan Pharmaceutical Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2023)
This chart shows how Shandong Realcan Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 002589 total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Shandong Realcan Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Shandong Realcan Pharmaceutical Co Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥-650.47 Million | -4.18% |
| Total Liquid Assets | CN¥-650.47 Million | -4.18% |
Asset Resilience Insights
- Limited Liquidity: Shandong Realcan Pharmaceutical Co Ltd maintains only -4.18% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Shandong Realcan Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shandong Realcan Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sigma Healthcare Ltd
AU:SIG |
Medical Distribution | 0.03% |
|
Cyclopharm Ltd
AU:CYC |
Medical Distribution | 1.98% |
|
Ebos Group Ltd
AU:EBO |
Medical Distribution | 0.00% |
|
Paragon Care Ltd
AU:PGC |
Medical Distribution | 0.00% |
|
Mayne Pharma Group Ltd
AU:MYX |
Medical Distribution | 4.00% |
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3 |
Medical Distribution | 4.48% |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607 |
Medical Distribution | 4.44% |
|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SHG:600332 |
Medical Distribution | 5.56% |
Annual Asset Resilience Ratio for Shandong Realcan Pharmaceutical Co Ltd (2015–2023)
The table below shows the annual Asset Resilience Ratio data for Shandong Realcan Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -3.99% | CN¥-666.13 Million ≈ $-97.48 Million |
CN¥16.71 Billion ≈ $2.45 Billion |
+1.98pp |
| 2022-12-31 | -5.97% | CN¥-1.09 Billion ≈ $-160.10 Million |
CN¥18.33 Billion ≈ $2.68 Billion |
-3.05pp |
| 2021-12-31 | -2.92% | CN¥-770.06 Million ≈ $-112.68 Million |
CN¥26.40 Billion ≈ $3.86 Billion |
-3.05pp |
| 2020-12-31 | 0.13% | CN¥40.79 Million ≈ $5.97 Million |
CN¥31.29 Billion ≈ $4.58 Billion |
-0.48pp |
| 2019-12-31 | 0.61% | CN¥198.09 Million ≈ $28.99 Million |
CN¥32.47 Billion ≈ $4.75 Billion |
+0.39pp |
| 2018-12-31 | 0.22% | CN¥77.83 Million ≈ $11.39 Million |
CN¥34.84 Billion ≈ $5.10 Billion |
+0.21pp |
| 2017-12-31 | 0.01% | CN¥2.54 Million ≈ $371.80K |
CN¥26.98 Billion ≈ $3.95 Billion |
+0.08pp |
| 2016-12-31 | -0.07% | CN¥-11.55 Million ≈ $-1.69 Million |
CN¥15.66 Billion ≈ $2.29 Billion |
+0.00pp |
| 2015-12-31 | -0.08% | CN¥-6.91 Million ≈ $-1.01 Million |
CN¥8.86 Billion ≈ $1.30 Billion |
-- |
About Shandong Realcan Pharmaceutical Co Ltd
Realcan Pharmaceutical Group Co., Ltd. sells medicines, medical devices, and medical consumables to medical institutions in China. It operates through the Drug and Equipment Distribution, In Vitro Diagnostics, Pharmaceutical Logistics, Traditional Chinese Medicine, and Microbiome Medicine segments. The company engages in the processing, manufacture, sale, and wholesale of Chinese medicinal materi… Read more